Investing or following the trends in Neuroscience in 2018?
Take the 3 minute Neuroscience - Pulse Survey
Which are the areas and companies to watch?
Key challenges?
Results will be shared.
Participation to result in donations for advocacy groups.

Neuroscience Pulse Survey

This 3 minute sponsored survey is aimed at gauging the perceptions of those following the Neuroscience Investment field. The sponsor is an an emerging pharmaceutical firm. Its name will be disclosed at the end of the survey. The results will be published on the sponsor's website and LinkedIn during our shortly after the JP Morgan conference. For your participation the sponsor will make a donation to a selection of charities.

Question Title

* 1. I am / work for:

Sell Side Biotech / Pharma Analyst

Buy Side Biotech / Pharma Analyst

Investment Fund Professional

Pharma / Biotech firm

Private Investor / Family Office

Consultant to Pharma / Biotech's (Physician and non-physician)

Investor Relations Professional

Blogger / Commentator

Other (please specify)

Question Title

* 2. The size of firms that I principally focus on, chose all that apply:

Large cap pharma/biotech

Mid cap pharma/biotech

Small cap pharma/biotech

Micro cap pharma/biotech

Emerging pre IPO private firms

Question Title

* 3. My ranking of the key challenges why Neuroscience is a high risk therapeutic area:

Novel science not proven enough (e.g. no biomarkers or not predictive, biological activity uncertain)

Regulatory path uncertainties

Reimbursement & commercial uncertainties (competition, generics, etc.)

Cost - Very high clinical trial investment (size of studies, number of studies, etc.)

Clinical trial execution too difficult (e.g. placebo response, recruitment challenges)

Question Title

* 4. In Neuroscience the areas most poised for a breakthrough within the next 2-3 years are:

Epilepsy

Alzheimer's

Multiple Sclerosis

Suicidal Ideation / Reduction of Suicide

Rare Neurological Disorders

Bipolar

Depression

Parkinson's

Anxiety

Schizophrenia

Pain

Other (please specify)

Question Title

* 5. In the area of Neurology the 3 companies (private and public) most likely to succeed with a significant approval in the next few years are:

Biogen

Eisai

Acorda Therapeutics

Teva

Eli Lilly

Roche Genentech

Novartis

Acadia

Axovant

Other (please specify)

Question Title

* 6. In the area of Psychiatry the 3 companies most likely to succeed with a significant approval in the next few years are:

Takeda

Allergan

Sage Therapeutics

Intra-Cellular Therapies

Alkermes

VistaGen

Sunovion (Sumitomo Dainippon Pharma Co.)

J&J

NeuroRx

Otsuka

Other (please specify)

Question Title

* 7. The one Psychiatric condition with the highest % of suicide attempts is:

Schizophrenia

Anxiety

Major Depressive Disorder including Treatment Resistant Depression

PTSD

Substance Abuse Disorder

Bipolar Disorder / Bipolar Depression

Other (please specify)

Question Title

* 8. In the area of Suicidal Ideation / Reduction of Suicidal Behavior the company (ies)(private or public) to watch for are:

Intra-Cellular Therapies

J&J

Allergan

VistaGen

NeuroRx

Don't know - I was not aware that suicidal ideation is an indication being pursued by firms

Other (please specify)

Question Title

* 9. The number of individuals that are lost to suicide in the USA every year is approximately

10,000 or less

10,000 to 20,000

20,000 to 30,000

30,000 to 40,000

40,000-50,000

Question Title

* 10. Thank you for participating in this survey - results will be published on our NeuroRx website during or shortly after the JPMorgan Conference. In appreciation of your participation, NeuroRx will make a donation to the below listed Patient Advocacy & Support groups. (They are not connected to this survey.)
Check which ones you know.

International Bipolar Foundation

HopeXchange Bipolar Support

JED Foundation

American Foundation for Suicide Prevention

Question Title

* 11.
THANK YOU FOR YOUR PARTICIPATION
RESULTS WILL BE PUBLISHED ON OUR NeuroRx Website
If you are interested in learning more about NeuroRx and its program in Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression, please share your contact info or visit our website.

Please also consider sharing this survey with your colleagues.
OPTIONAL CONTACT INFO

My name:

My email: